CD8A and neoplasm: Additionally, DCs engineered to secrete IL-12 or express CD40L may strengthen T-cell activation and improve CD8+ T cell mediated anti-tumor responses known in lung cancer to occur more robustly in tumors with higher neo-antigen burden (8).